Daily Newsletter

09 October 2024

Daily Newsletter

09 October 2024

Caldera Medical expands hysteroscopy offerings with UVision360 acquisition

The acquisition enables Caldera Medical to provide solutions to treat gynaecological conditions such as polyps and fibroids.

RanjithKumar Dharma October 09 2024

Caldera Medical has expanded its hysteroscopy portfolio with the acquisition of UVision 360, the creator of the LUMINELLE hysteroscopy and cystoscopy systems.

This move enhances Caldera Medical's minimally invasive portfolio, offering advanced solutions for the diagnosis and treatment of gynaecological conditions like fibroids, polyps and intrauterine pathology.

The LUMINELLE system offers high-resolution optics and user-friendly design, providing a cost-effective option for both therapeutic and diagnostic hysteroscopy.

It is compatible with current surgical workflows as it serves as a desirable choice for gynaecologic surgeons aiming for minimally invasive solutions that improve procedural accuracy and patient recovery time.

Caldera Medical CEO Bryon Merade said: “We are excited to integrate LUMINELLE's technology into Caldera Medical’s growing portfolio.

“This acquisition strengthens our commitment to offering gynecologic surgeons state-of-the-art tools that streamline hysteroscopic procedures while enhancing patient safety and clinical outcomes."

The integration of the company’s Benesta product line with LUMINELLE provides enhanced procedural capabilities for gynaecologic surgeons.

This combination is set to improve clinical outcomes for a variety of intrauterine treatments such as biopsies, polypectomies and fibroid resections, in office settings as well as surgical environments.

LUMINELLE CEO and co-founder Allison London Brown said: “The LUMINELLE team has worked diligently to finally provide an accurate and easy diagnosis to a growing deadly disease, uterine cancer.

“We are excited that Caldera Medical shares our vision and will accomplish this mission.”

Caldera Medical offers a portfolio that can be used for treatments such as pelvic organ prolapse, stress urinary incontinence and gynaecologic conditions.

The company has partnered with its surgeon partners to operate a humanitarian programme in women’s health.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close